These oncogenic mutations cause EGFR antibody resistance in CRC cell lines, and patient-derived xenografts with S310F, L755S, V777L, V842I, and L866M mutations show durable tumor regression when treated with dual HER2-targeted therapy [9]. Here, ERBB2 is linked to neoplasm.